Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Irritable Bowel Syndrome01:23

Irritable Bowel Syndrome

DefinitionIrritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by recurrent combinations of abdominal pain, bloating, diarrhea, or constipation.Pathophysiology of irritable bowel syndromeIts pathophysiology is multifactorial, involving disturbances in motility, sensory processing, microbial balance, barrier integrity, and gut–brain communication. These mechanisms interact to produce symptoms that vary across IBS subtypes.Altered Motility PatternsDisordered...
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Physiology of Enteric Nervous System and Gut Health01:05

Physiology of Enteric Nervous System and Gut Health

The gastrointestinal tract, responsible for the digestion and absorption of nutrients, is safeguarded by the intestinal barrier, which consists of secretory, physical, and immune components. At the forefront is the secretory barrier, composed of essential elements such as mucus, gut microbiota, and defense proteins. They collaborate to break down food particles, facilitate nutrient absorption, and maintain optimal gut health. These secretory components ensure the smooth functioning of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recent advances in our understanding of the gut microbiome: an analysis from the Gut Microbiota for Health Expert Panel of the British Society of Gastroenterology.

Gut·2026
Same author

Beyond unconscious bias: A practical model for improving equality and inclusion.

Clinical medicine (London, England)·2025
Same author

Consensus on Safe Initiation and Monitoring of Transanal Irrigation to Optimize Adherence With Therapy.

Neurogastroenterology and motility·2025
Same author

Association between a selective 5-HT<sub>4</sub> receptor agonist and incidence of major depressive disorder: emulated target trial.

The British journal of psychiatry : the journal of mental science·2024
Same author

Comments on 'Life-threatening bowel complications in adults with Duchenne muscular dystrophy: A case series' - Response.

Neuromuscular disorders : NMD·2024
Same author

When tackling racism is everyone's problem, it becomes no one's.

BMJ (Clinical research ed.)·2024
Same journal

Anti-fibrotic therapy in Crohn's disease: hype or reality-can intestinal fibrosis be targeted effectively?

Expert review of gastroenterology & hepatology·2026
Same journal

Management of gastric varices: treatment options and opportunities to improve outcomes.

Expert review of gastroenterology & hepatology·2026
Same journal

Microbial ecology and hepatocellular carcinoma: should a subset be viewed as a microbiome-conditioned malignancy?

Expert review of gastroenterology & hepatology·2026
Same journal

FAPI PET in inflammatory bowel disease: a novel window on fibroblast activity, with unanswered clinical questions.

Expert review of gastroenterology & hepatology·2026
Same journal

Lyon Consensus 2.0: what has changed for GERD diagnosis?

Expert review of gastroenterology & hepatology·2026
Same journal

Proton pump inhibitors in children: indications and safety.

Expert review of gastroenterology & hepatology·2026
See all related articles

Related Experiment Video

Updated: May 11, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Systemic sclerosis and the gut.

Shamaila Butt1, Anton Emmanuel

  • 1Gastrointestinal Physiology unit, University College Hospital, London, UK. s.butt@ucl.ac.uk

Expert Review of Gastroenterology & Hepatology
|May 4, 2013
PubMed
Summary
This summary is machine-generated.

Systemic sclerosis (SSc) frequently causes gastrointestinal (GI) issues, impacting patient health. This review covers emerging treatments for lower GI symptoms and the connection between reflux and lung disease in SSc patients.

More Related Videos

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

Related Experiment Videos

Last Updated: May 11, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

Area of Science:

  • Gastroenterology
  • Rheumatology
  • Internal Medicine

Background:

  • Gastrointestinal (GI) involvement is a significant cause of morbidity and mortality in systemic sclerosis (SSc).
  • GI complications affect up to 90% of SSc patients, second only to skin manifestations.
  • Current treatments for upper GI symptoms like reflux remain limited, while lower GI symptoms present evolving therapeutic options.

Purpose of the Study:

  • To review the current understanding and management of GI symptoms in systemic sclerosis (SSc).
  • To highlight emerging treatment modalities for lower GI complications in SSc.
  • To address the association between reflux and interstitial lung disease in SSc.

Main Methods:

  • Literature review focusing on gastrointestinal manifestations in systemic sclerosis.
  • Analysis of current and emerging treatment strategies for upper and lower GI symptoms.
  • Examination of the relationship between GI reflux and interstitial lung disease in SSc.

Main Results:

  • Gastrointestinal complications are highly prevalent in systemic sclerosis.
  • Emerging treatments show promise for managing constipation and fecal incontinence in SSc.
  • A significant link exists between GI reflux and interstitial lung disease in SSc patients.

Conclusions:

  • Effective management of GI symptoms is crucial for improving outcomes in SSc.
  • Further research into novel therapies for GI manifestations in SSc is warranted.
  • Understanding the GI-lung axis in SSc is essential for comprehensive patient care.